Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pardoprunox adjunct to L-dopa versus pramipexole in advanced Parkinson's disease with motor fluctuations and dyskinesia
2008-000400-81Phase 2Terminated
- Sponsor
- Solvay
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pardoprunox in Parkinson's disease (PD) (2 arms), sponsored by Solvay. Primary endpoint: Change from baseline to maintenance Week 12 or endpoint in ON time without dyskinesia. Started Jan 2009; status: terminated.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2008-000400-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000400-81.